Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - Moreno, Carol; Greil, Richard; Demirkan, Fatih; Tedeschi, Alessandra; Anz, Bertrand; Larratt, Loree; Simkovic, Martin; Samoilova, Olga; Novak, Jan; Ben-Yehuda, Dina; Strugov, Vladimir; Gill, Devinder; et al. (The lancet oncology, 2019)
Keywords: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cardiac arrhythmia; Chemotherapy; Chlorambucil; Chlorambucil - administration & dosage; Chlorambucil - adverse effects; Chlorambucil - therapeutic use; Chronic lymphocytic leukemia; Cytogenetics; Dyspnea; Female; Hematology, Oncology, and Palliative Medicine; Humans; Hyperglycemia; Immunotherapy; Inhibitor drugs; Intention to Treat Analysis; Intravenous administration; Kinases; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Lymphoma; Male; Monoclonal antibodies; Mutation; Neuroendocrine tumors; Neutropenia; Neutrophils; Oncology; Patients; Progression-Free Survival; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Skin; Skin cancer; Survival; Targeted cancer therapy; Thrombocytopenia; Treatment Outcome